ALCAR decreases fatigue and protects the liver in patients being treated for hepatitis C

October 20, 2011

     Doctors at the University of Catania in Italy treated sixty patients chronically infected with hepatitis C with the drugs Ribavirin and Pegylated Interferon for 12-months. This combination is frequently effective for treating the disease but often is discontinued by the patient prematurely because of side effects that include fatigue and flu like symptoms (headache, muscle ache, fever).
     In half the patients they added ALCAR (N-Acetyl-L-Carnitine) to improve quality of life and thereby decrease the risk of discontinuing treatment due to side effects.
     At the end of 12-months adding ALCAR significantly reduced liver enzyme levels showing that ALCAR had strong liver protecting effects. ALT was 23 points lower and AST was 30 points lower in the ALCAR group. ALCAR also reduced viremia (the level of virus in the blood significantly. ALCAR strongly improved mental health, physical function, body pain and general health. Vitality, social functioning, physical fatigue and mental fatigue all improved on ALCAR and it improved the patient’s quality of life. The study is published in the September 2011 issue of the Journal of Interferon and Cytokine Research.